CoChat

Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder

Open access
Boulenger, Jean-Philippe, Loft, Henrik, Olsen, Christina Kurre · 2014 · International Clinical Psychopharmacology

The DOI matches its Crossref record, with a small difference in title or year; 33 of the 34 references it cites were found in a registry or an index.

Abstract

This study assessed the efficacy, tolerability and safety of vortioxetine versus placebo in adults with recurrent major depressive disorder. This double-blind, randomized, placebo-controlled study included 608 patients [Montgomery-Åsberg Depression Rating Scale (MADRS) total score ≥ 26 and Clinical Global Impression - Severity score ≥ 4]. Patients were randomly assigned (1 : 1 : 1 : 1) to vortioxetine 15 mg/day, vortioxetine 20 mg/day, duloxetine 60 mg/day or placebo. The primary efficacy endpoint was change from baseline in MADRS total score at week 8 (mixed model for repeated measurements). Key secondary endpoints were: MADRS responders; Clinical Global Impression - Improvement scale score; MADRS total score in patients with baseline Hamilton Anxiety Rating Scale ≥ 20; remission (MADRS ≤ 10); and Sheehan Disability Scale total score at week 8. On the primary efficacy endpoint, both vortioxetine doses were statistically significantly superior to placebo, with a mean difference to placebo (n = 158) of -5.5 (vortioxetine 15 mg, P < 0.0001, n = 149) and -7.1 MADRS points (vortioxetine 20 mg, P < 0.0001, n = 151). Duloxetine (n = 146) separated from placebo, thus validating the study. In all key secondary analyses, both vortioxetine doses were statistically significantly superior to placebo. Vortioxetine treatment was well tolerated; common adverse events (incidence ≥ 5%) were nausea, headache, diarrhea, dry mouth and dizziness. No clinically relevant changes were seen in clinical safety laboratory values, weight, ECG or vital signs parameters. Vortioxetine was efficacious and well tolerated in the treatment of patients with major depressive disorder.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/yic.0000000000000018

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Flow chart of patient disposition. AEs, adverse events; APTS, all-patients-treated set; CGI-S, Clinical Global Impression – Severity; FAS, full-analysis set; LFU, lost to follow-up; LoE, lack of efficacy; MADRS, Montgomery–Åsberg Depression Rating Scale; NC, noncompliance; PV, protocol violation; WoC, patient consent withdrawn. *Three patients had a MADRS total score<26 and/or CGI-S score<4. **Patients with a valid postbaseline MADRS assessment. ‡Including one patient withdrawn from the FAS due to no postbaseline MADRS assessment.
Fig. 1 Flow chart of patient disposition. AEs, adverse events; APTS, all-patients-treated set; CGI-S, Clinical Global Impression – Severity; FAS, full-analysis set; LFU, lost to follow-up; LoE, lack of efficacy; MADRS, Montgomery–Åsberg Depression Rating Scale; NC, noncompliance; PV, protocol violation; WoC, patient consent withdrawn. *Three patients had a MADRS total score<26 and/or CGI-S score<4. **Patients with a valid postbaseline MADRS assessment. ‡Including one patient withdrawn from the FAS due to no postbaseline MADRS assessment.CC BY-NC-ND · PubMed Central
Fig. 2 Estimated Montgomery–Åsberg Depression Rating Scale (MADRS) total scores from baseline to week 8 (FAS, MMRM by visit) and LOCF (FAS, ANCOVA). Patient numbers at each visit are shown below the x-axis for each treatment group. *P<0.05; **P<0.01; ***P<0.001 versus placebo. ANCOVA, analysis of covariance; DUL, duloxetine; FAS, full-analysis set; LOCF, last observation carried forward; MMRM, mixed model, repeated measures; PBO, placebo.
Fig. 2 Estimated Montgomery–Åsberg Depression Rating Scale (MADRS) total scores from baseline to week 8 (FAS, MMRM by visit) and LOCF (FAS, ANCOVA). Patient numbers at each visit are shown below the x-axis for each treatment group. *P<0.05; **P<0.01; ***P<0.001 versus placebo. ANCOVA, analysis of covariance; DUL, duloxetine; FAS, full-analysis set; LOCF, last observation carried forward; MMRM, mixed model, repeated measures; PBO, placebo.CC BY-NC-ND · PubMed Central
Fig. 3 Estimated Hamilton Rating Scale for Anxiety (HAM-A) total scores from baseline to week 8 (FAS, MMRM by visit) and LOCF (FAS, ANCOVA). Patient numbers at each visit are shown below the x-axis for each treatment group. **P<0.01; ***P<0.001 versus placebo. ANCOVA, analysis of covariance; DUL, duloxetine; FAS, full-analysis set; LOCF, last observation carried forward; MMRM, mixed model, repeated measures; PBO, placebo.
Fig. 3 Estimated Hamilton Rating Scale for Anxiety (HAM-A) total scores from baseline to week 8 (FAS, MMRM by visit) and LOCF (FAS, ANCOVA). Patient numbers at each visit are shown below the x-axis for each treatment group. **P<0.01; ***P<0.001 versus placebo. ANCOVA, analysis of covariance; DUL, duloxetine; FAS, full-analysis set; LOCF, last observation carried forward; MMRM, mixed model, repeated measures; PBO, placebo.CC BY-NC-ND · PubMed Central
Fig. 4 Mean Discontinuation-Emergent Signs And Symptoms (DESS) total score at baseline (week 8), at 1 week (week 9) and 2 weeks (week 10) after tapered discontinuation of treatment (APCS, OC, ANCOVA). *P<0.05; ***P<0.001 versus placebo. ANCOVA, analysis of covariance; APCS, all-patients-completed set; OC, observed cases.
Fig. 4 Mean Discontinuation-Emergent Signs And Symptoms (DESS) total score at baseline (week 8), at 1 week (week 9) and 2 weeks (week 10) after tapered discontinuation of treatment (APCS, OC, ANCOVA). *P<0.05; ***P<0.001 versus placebo. ANCOVA, analysis of covariance; APCS, all-patients-completed set; OC, observed cases.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Cited by

See all 203

Metadata

Authors
Boulenger, J.-P., Loft, H., & Olsen, C. K.
Affiliations
  • Centre Hospitalier Universitaire de Montpellier (FR)
  • Lundbeck (Denmark) (DK)
Corresponding author
Boulenger, Jean-Philippe
Venue
International Clinical Psychopharmacology
Published
2014-05
Volume
29
Issue
3
Pages
138-149
ISSN
0268-1315 (ISSN-L)
OpenAlex
W2001782289
Cited by
176
References
34
Citations by year
2026: 4 · 2025: 14 · 2024: 10 · 2023: 11 · 2022: 11 · 2021: 10 · 2020: 7 · 2019: 15 · 2018: 14 · 2017: 17 · 2016: 16 · 2015: 29 · 2014: 16
FWCI
15.42
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • International Clinical Psychopharmacology (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
H. Lundbeck A/S
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
Keywords
vortioxetine, major depressive disorder, duloxetine, antidepressant efficacy, drug safety, tolerability, dose comparison, recurrent depression, adverse events, remission, disability
MeSH terms
Duloxetine Hydrochloride, Vortioxetine, Adolescent, Adult, Aged, Major Depressive Disorder, Double-Blind Method, Female, Headache, Humans, Male, Middle Aged, Nausea, Piperazines, Psychiatric Status Rating Scales, Sulfides, Thiophenes, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Internationality, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. https://app.cochat.ai/papers/10.1097/yic.0000000000000018
The paper
Boulenger, J.-P., Loft, H., & Olsen, C. K. (2014). Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. International Clinical Psychopharmacology. https://doi.org/10.1097/yic.0000000000000018

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.